<DOC>
	<DOCNO>NCT01439828</DOCNO>
	<brief_summary>The primary purpose ass efficacy human N-acetylcysteine versus placebo 4 week cannabis withdrawal .</brief_summary>
	<brief_title>Clinical Trial N-acetylcysteine Versus Placebo Efficacy Cannabis Withdrawal</brief_title>
	<detailed_description>Introduction : There clinical trial pharmacotherapies marijuana dependence . There randomized double-blind trial N-acetylcysteine efficacy marijuana withdrawal.Aims : The first aim ass efficacy human ( n=150 outpatient ) N-acetylcysteine versus placebo 4 week cannabis withdrawal.The secondary aim : a-Assessing abstinence next 5 month follow-up.b-Assessing correlation genetic characteristic : cytochrome CYP2C9 CYP3A4 , CNR1 receptor , Fatty Amide Hydroxylase ( FAAH ) , dopamine DAT transporter Catechol-O-MéthylTransférase ( COMT ) ; three phenotype : 1. cannabis level consumption , 2. cannabis abuse dependence ( DSM-IV ) , 3. cannabis withdrawal.c-Assessing tobacco consumption ( Fagerström test ) , NICOTINIQUE receptor CHRA3 cannabis quit success.Subjects:150 cannabis outpatient , seek treatment LARIBOISIERE hospital cannabis set , cut cannabis use.Inclusion criterion : &gt; 18 year old , pregnant breast feeding , cannabis abuse dependence diagnosis ( DSM-IV ) , acceptance trial consent sign , validate ethic committee.Methods : Randomized double-blind trial.Visit 0 : Clinical assessment trial presentation , Validate inclusion non- inclusion criteria.Visit 1 : Consent sign . Blood urine analysis . Questionnaires assess cannabis tobacco 's craving.NAC placebo dos increase crave decrease &lt; 25 % compare previous visit . The dos start 200 mg x 4/24h 800 mg x 4/24h.Visit 2 5 : Medication safety cannabis crave withdrawal assessment 4 weeks.Visit 5 : Blood urine analysis.Visit 6 8 : abstinence assessment 5 months.Goals : Efficacy assessment N-Acetylcysteine cannabis withdrawal abstinence compare placebo . Assessment NAC efficacy cannabis craving . The length study 6 month evaluate abstinence persistence . Evaluation clinical , biological genetic factor associate abstinence success.Statistic : Sample size : A two group continuity correct c2 test 0.050 two-sided significance level 80 % power detect difference Group 1 proportion , p1 , 0.250 Group 2 proportion , p2 , 0.500 ( odds ratio 3.000 ) sample size group 66 . Taking account rate lose follow-up around 15 % total sample size study fix N= 150 patients.Main criterion binary secondary criterion analyse Chi-square test Fisher 's exact probability test . Relationships genotype phenotype analyse multivariate logistic model</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>&gt; 18 year old Not pregnant breast feeding Cannabis abuse dependence diagnosis ( DSMIV ) Acceptance trial consent sign , validate ethic committee Patient affiliate social insurance care Contraindication Nacetylcystein : allergic Nacetylcystein , severe allergic illness , PHENYLCETONURIA , lactose intolerance , gastroduodenal ulcer . Severe somatic disease stabilize : diabetes , epilepsia , recent myocardial infarct , asthma . Severe mental disease stabilize : schizophrenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Cannabis</keyword>
	<keyword>N-Acetylcystein</keyword>
	<keyword>Dependence</keyword>
	<keyword>Abuse</keyword>
	<keyword>Craving</keyword>
	<keyword>Genetic</keyword>
</DOC>